Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 1, 6Email author,
  • 4, 5 and
  • 4, 5
Contributed equally
World Journal of Surgical Oncology201311:149

https://doi.org/10.1186/1477-7819-11-149

  • Received: 26 March 2013
  • Accepted: 26 March 2013
  • Published:

The original article was published in World Journal of Surgical Oncology 2011 9:59

Correction

After the publication of this work [1], we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’.

We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.

Notes

Authors’ Affiliations

(1)
Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao, 266003, R. P. China
(2)
Pathology, the Affiliated Hospital of Medical College, QingDao University, QingDao, Shan Dong Province, 266003, P. R. China
(3)
Molecular Biology, the Affiliated Hospital of Medical College, QingDao University, QingDao, Shan Dong Province, 266003, P. R. China
(4)
Hepatobiliary surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China
(5)
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
(6)
Department of Surgery, the Affiliated Hospital of Medical College, QingDao University, No 16 Jiangsu Road, Qingdao, Shan Dong Province, 266003, P. R. China

References

  1. Chen : Clusterin confers gmcitabine resistance in pancreatic cancer. World J Surg Oncol. 2011, 9: 59-10.1186/1477-7819-9-59.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

Advertisement